Markets & Investing
BREAKING: Kentucky To Invest in Ibogaine Treatment for Addiction
Earlier today during a press conference, the Opioid Abatement Advisory Commission held a press conference announcing its intended focus on treatments for…
Earlier today during a press conference, the Opioid Abatement Advisory Commission held a press conference announcing its intended focus on treatments for addiction, most specifically ibogaine treatments for opioid addiction.
Approximately $42 million will be allocated over the next seven years to develop safety protocols and to host clinical trials for ibogaine.
“Ibogaine is an alkaloid derived from three plant sources” found in West African countries. “Anecdotal evidence that is a mountain high and decades wide suggests that ibogaine, within 48 to 72 hours of administration in safe, clinically-controlled conditions, resolves opioid withdrawal syndrome,” exclaimed W. Bryan Hubbard, who chairs the Kentucky Commission.
W. Bryan Hubbard, Kentucky’s Opioid Advisory Commission Chair“If this anecdotal evidence can be clinically validated, ibogaine would represent a transformative therapeutic or treatment of opioid use disorder.”
We’ll continue to follow this story, and other similar cases, as it/they develop.
-
Law & Regulation1 week ago
Relmada Therapeutics trims losses, slashes research costs
-
Psychedelics1 week ago
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
-
Psychedelics1 week ago
Numinus Wellness Submits Clinical Trial Application
-
Psychedelics1 week ago
Elon Musk Continues To Defend Ketamine
-
Psychedelics1 week ago
Psyence Biomedical Ltd. Announces Results of Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin
-
Psychedelics1 week ago
MindBio Therapeutics Corp. Begins Phase 2B Take-Home Microdosing Clinical Trial in Patients with Major Depressive Disorder
-
Psilocybin7 days ago
Indigenous Psilocybin Practices Around the World
-
Psychedelics1 week ago
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas